# First-line Combination Treatment Based on Anlotinib

> **NCT03628521** · PHASE1 · UNKNOWN · sponsor: **Shanghai Chest Hospital** · enrollment: 80 (estimated)

## Conditions studied

- Lung Cancer
- Advanced Stage

## Interventions

- **DRUG:** Anlotinib，Erlotinib，IBI308，Pemetrexed，gemcitabine，carboplatin

## Key facts

- **NCT ID:** NCT03628521
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-20
- **Primary completion:** 2019-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2018-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03628521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03628521, "First-line Combination Treatment Based on Anlotinib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03628521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*